<DOC>
	<DOCNO>NCT01969201</DOCNO>
	<brief_summary>The purpose non-inferiority study evaluate clinical efficacy safety two different subcutaneous FSH preparation ( Fostimon versus Gonal-F ) control ovarian hyperstimulation GnRH-antagonist cycle .</brief_summary>
	<brief_title>FSH GnRH-AntagoniST Controlled Ovarian Hyperstimulation Cycles ( FAST )</brief_title>
	<detailed_description />
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Ovarian Hyperstimulation Syndrome</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Follicle Stimulating Hormone</mesh_term>
	<criteria>Age : 1838 year old ; BMI : 1828 kg/m2 ; Less 3 previously complete IVF cycle ; Basal FSH &lt; 10 IU/L E2 &lt; 80 pg/ml ; TSH &lt; 2.5 mIU/L &gt; 10 &lt; 30 antral follicle 210 mm size ovary combine AMH : &gt; 1 ng/ml ( 7.15 pmol/l ) &lt; 5.6 ng/ml ( 40.0 pmol/l ) Presence adequate visualization ovary ; Within 12 month begin study , uterine cavity consistent expect normal function assess transvaginal ultrasound , hysterosalpingogram , sonohysterogram hysteroscopic examination ; Primary ovarian failure woman know poor responder ; PCO PCOS ; Severe OHSS previous COH cycle ; Uterine malformation may impair possibility get pregnant ; Ovarian cyst &gt; 10 mm ; Hydrosalpinx surgically remove ligate ; Endometriosis stage 3 4 ; Oocyte donation ; Severe male factor ; Pathologies associate contraindication pregnant ; History recurrent miscarriage ( 3 previous miscarriage ) ; Hypersensitivity study medication ; Abnormal bleeding undetermined origin ; Uncontrolled thyroid adrenal dysfunction ; Neoplasias ; Severe impairment renal and/or hepatic function .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>38 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>In vitro fertilization ( IVF )</keyword>
	<keyword>Assisted reproduction technology ( ART )</keyword>
	<keyword>GnRH-antagonist</keyword>
	<keyword>Follicle stimulate hormone ( FSH )</keyword>
</DOC>